References
- Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004; 364: 985–96
- Barnes PJ. ABC of chronic obstructive pulmonary disease: future treatments. Br Med J 2006; 333: 246–8
- Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775–83
- Nannini L, Cates C, Lasserson T, Poole P. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; 3: CD003794
- Van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22
- Frishman WH, Mitta W, Kupersmith A, Ky T. Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol Rev 2006; 14: 57–73
- Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharm Rev 2004; 56: 515–48
- Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006; 27: 546–53
- Fan CK. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533: 110–7
- Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004; 1: 264–8
- Barnes PJ. Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opin Ther Targets 2005; 9: 1111–21
- Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25: 1084–106